A newly revealed customs contract shows US Border Patrol has a £55,000 ($75,000) taxpayer-funded deal with Four Seasons Pet ...

Absci (NASDAQ:ABSI) used a presentation at the 44th JPMorgan Healthcare Conference to outline recent platform updates and ...

Illumina launched the Billion Cell Atlas to train AI on one billion single cells. AstraZeneca, Merck and Lilly are founding ...

The site, which will cost about €10.0 billion ($11.7 billion) to complete, will be the third-largest of the company’s Verbund ...

World Premiere of SPARE PARTS A New Play about Science, Ambition & the Human Soul Written by DAVID J. GLASS and ...

Condé Nast Traveler readers believe this major US city is the end-all-be-all for shopping destinations in the country.

Aurora Therapeutics today announced its official launch to transform personalized gene editing from a one-patient breakthrough into a scalable model capable of bringing therapies to millions of ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...